Mayo Clinic: COVID-19 vaccines are 88.7% effective in the ‘real world’


Both of the authorized COVID-19 vaccines in the U.S. are nearly as effective at preventing infections with SARS-CoV-2 in the real world as they were in clinical trials, according to new research conducted by the Mayo Clinic and Nference Inc., a privately held company. The study, which was published Thursday as a preprint, found that both COVID-19 vaccines had an effective rate of 88.7% in the roughly 62,000 people included in the retrospective analysis. It also found that people who had been vaccinated had lower hospitalization rates if they did get sick. The vaccine developed by BioNTech SE
and Pfizer Inc.
had an efficacy rate of 95.0% in the Phase 3 clinical trial, while Moderna Inc.’s
vaccine reported an efficacy rate of 94.1% in its late-stage study. Both are mRNA-based vaccines that require two doses and received emergency use authorization from the Food and Drug Administration in December. The slightly lower effectiveness rate is likely due to the fact that the vaccination was initially only open to two groups of people who are at high risk for contracting the virus: health care workers, and nursing-home residents. Over the past 12 months, shares of BioNTech have soared 249.3%, Pfizer’s stock is up 0.7%, and Moderna shares have rallied 796.2% The broader S&P 500
is up 16.3%.


- Advertisement -

Leave A Reply

Your email address will not be published.